Disease relevance of Femstat

• Most responders (64%) agreed that pharmacists could provide, without a prescription, a 3-day course of a vaginal cream containing 2% butoconazole for vaginal candidiasis in nonpregnant women and a rectal suppository containing steroids for hemorrhoid sufferers (61%) [1].
• Patient acceptance of a new, compact, prefilled disposable vaginal applicator was tested in an open study in which 2% butoconazole cream was used for the treatment of vulvovaginal candidiasis [2].
• The anti-inflammatory activities of eight anti-fungal agents (butoconazole, ciclopirox olamine, fluconazole, miconazole nitrate, sertaconazole nitrate, terconazole, tioconazole and ketoconazole) were compared in a number of preclinical models of dermal inflammation and pruritus [3].
• While butoconazole, ciclopirox olamine, fluconazole, and miconazole nitrate were all found to have anti-inflammatory activity, only sertaconazole nitrate reduced the release of cytokines from activated lymphocytes and mitigated inflammation in animal models of irritant contact dermatitis and neurogenic inflammation [3].
• A short-duration treatment for candidal vaginitis applying butoconazole in situ was tested in an experimental mouse model [4].

Psychiatry related information on Femstat

• The advantage of the shorter butoconazole treatment is increased patient compliance with maintenance of high efficacy [5].

High impact information on Femstat

• At 8 X 10(-5) M, butoconazole, oxiconazole, and sulconazole were strictly fungistatic against early stationary phase Candida albicans cells diluted into fresh medium [6].
• Antifungal relative inhibition factors: BAY l-9139, bifonazole, butoconazole, isoconazole, itraconazole (R 51211), oxiconazole, Ro 14-4767/002, sulconazole, terconazole and vibunazole (BAY n-7133) compared in vitro with nine established antifungal agents [7].
• Both drugs significantly reduced all signs and symptoms, and at visits 2 and 3 the percentages of patients considered microbiologically, clinically and therapeutically cured were consistently higher for butoconazole- than for econazole-treated patients, although differences were not statistically different [8].
• Severe reversible thrombocytopenia resulting from butoconazole cream [9].
• A 54-year-old woman with a 19-year history of rheumatoid arthritis developed life-threatening thrombocytopenia one week after beginning butoconazole therapy for a vaginal yeast infection [9].

Chemical compound and disease context of Femstat

• Complete absence of the entrance signs and symptoms of vulvovaginal candidiasis was noted in 82% of patients receiving butoconazole and 72% of patients receiving clotrimazole [10].
• In a single blind trial, a three day course of butoconazole nitrate cream was compared with a seven day course of miconazole nitrate cream, both applied intravaginally, in treating vaginal candidiasis [11].
• An evaluation of butoconazole nitrate 2% site release vaginal cream (Gynazole-1) compared to fluconazole 150 mg tablets (Diflucan) in the time to relief of symptoms in patients with vulvovaginal candidiasis [12].
• Butoconazole is a new imidazole, effective as therapy for vulvovaginal candidiasis for women who prefer solid-type vaginal preparations [13].
• A comparison of butoconazole nitrate cream with econazole nitrate cream for the treatment of vulvovaginal candidiasis [8].

Analytical, diagnostic and therapeutic context of Femstat

• The specimens were analyzed for butoconazole content using high-performance liquid chromatography [14].
• Thirty days after treatment completion, 73% of the butoconazole-treated patients and 69% of the miconazole-treated patients remained Candida negative; 78% of the butoconazole-treated patients and 80% of the miconazole-treated patients remained free of clinical symptoms of vulvovaginitis [5].

References